NC
DFTX

NewSquare Capital’s Definium Therapeutics DFTX Stock Holding History

NewSquare Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17
Closed -$61 – 773
2023
Q2 		$61 Hold
17
– – ﹤0.01% 814
2023
Q1 		$54 Hold
17
– – ﹤0.01% 848
2022
Q4 		$37 Buy
+17
New +$47 ﹤0.01% 801

Other funds holding DFTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

NewSquare Capital's DFTX Position: Q3 2023 in Review

NewSquare Capital sold out of Definium Therapeutics (DFTX) in Q3 2023, closing a stake of 17 shares — an estimated $61 sold.

NewSquare Capital first reported a position in DFTX in Q4 2022 and held it in 3 quarters. The position peaked at $61 in Q2 2023. 93 funds tracked by Wall St. Rank hold DFTX as of Q3 2023.

  • NewSquare Capital reported no remaining Definium Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 17 Definium Therapeutics shares in Q3 2023, an estimated $61.
  • NewSquare Capital first reported a position in Definium Therapeutics in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Definium Therapeutics position peaked at $61 in Q2 2023.
  • 93 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.